Topic 1: Foundations in Opioid Use Disorder (OUD) and OUD Treatment

Q&A Making Strong Referrals for Opioid Use Disorder Treatment

Activity Details
  • Credit Amounts:
    • CME: 1.25
    • CPE: 1.25
    • ASWB ACE: 1.25
    • CNE: 1.25
  • Cost: Free
  • Release: Feb 16, 2024
  • Expires: Feb 15, 2027
  • Estimated Time to Complete:
    1 Hour(s)  15 Minutes
  • Average User Rating:
    ( Ratings)

Q&A Making Strong Referrals for Opioid Use Disorder Treatment enduring module is a recording from the live Regularly Scheduled Series dated April 20, 2023. If you claimed credit for this session at the live meeting, you should not claim credit for this module.


McKenzie Clarke McKenzie Clarke, LSW
HEALing Transitions
Bluegrass Care Navigators
Lexington, Kentucky

Linda G.  Edwards Linda G. Edwards, CADC
Alcohol/Drug Counselor
Targeted Case Manager
Retention Navigator
HEALing Transitions
Bluegrass Care Navigators
Lexington, Kentucky

Emily Sprouse Emily Sprouse, CSW
Social Worker
Retention Navigator
HEALING Transitions
Bluegrass Care Navigators
Lexington, Kentucky

Needs Statement

Individuals with substance use disorders often face barriers to seeking sustainable resources to improve their recovery capital.  Transition between care settings presents vulnerabilities to individuals with SUD who are seeking resources

Target Audience

Physicians, Nurses, Nurse Practitioners, Physician Assistants, Pharmacists, Social Workers


Upon completion of this activity, participants will be able to:

  1. Identify vulnerabilities and common barriers faced by individuals with substance use disorders
  2. Identify supportive and high-quality referrals for individuals with substance use disorders
  3. Explain the importance of thorough, active referrals during times of transition, as this is a vulnerable time for those with SUD
  4. Describe how to maintain a person-centered approach to reach the client's goals


In support of improving patient care, University of Kentucky HealthCare CECentral is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This enduring material is designated for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

This training has been approved by the KBML as meeting the statutory requirements of HB1. 0423-H1.5-UKHC/Apr23

IPE Competencies

  • Values/Ethics for Interprofessional Practice
  • Roles/ Responsibilities
  • Interprofessional Communication
  • Teams and Teamwork

This knowledge-based activity will award 1.25 contact hours (0.125 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

As a Jointly Accredited Organization, UK HealthCare CECentral is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. UK HealthCare CECentral maintains responsibility for this course. Social workers completing this course receive 1.25 clinical continuing education credits.

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.25 nursing contact hours.

Faculty Disclosure

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation


In collaboration with UK Substance Use Research Priority Area.